Skip to main content Deutsch

ART 2023 - Advanced Retinal Therapy

09. December 2023 | Van Swieten Saal, Van-Swieten-Gasse 1a, 1090 Vienna
Sorry, this content is only available in German!

It is a great pleasure and privilege to invite you to the 20th ART Vienna conference on advanced retinal therapy in the year of 2023.

There is no doubt that innovation has continued its dynamic force supported by advanced technology leading to a substantial increase in knowledge, particularly in retina. Exchange of insight and expertise, clinical and scientific results and active initiatives are vital for bringing “codes to clinic” and quality to patients.

Our team has put together three major sessions with the topics

  • The most important and educative cases of my entire career
  • Artificial Intelligence in the management and understanding of retinal disease: Benefits and challenges
  • Unmet needs in the management of retinal disease
  • The future is here to stay

We have invited speakers that have excelled in moving the field towards new horizons.

For a lively exchange of ideas and a robust understanding of contents, face-to-face encounters are essential. This year’s conference can provide this most important inter-individual exchange again. Interactive discussion and debate will be strengthened by having panel discussions with participation of all speakers in small groups related to their comment topic.

With this spirit of moving the field of retina ahead in a collaborative and person-driven effort, we are very much looking forward to see and hear you on
December 9th, 2023.

Univ.-Prof. Dr. Ursula Schmidt-Erfurth
Professor and Chair

Medical University Vienna
Department of Ophthalmology and Optometry

Austrian Academy of Sciences
Full member


Register now


Ursula Schmidt-Erfurth

08:15 - 09:00
The most important and educative cases of my entire career
Moderators: Lee Jampol, Anita Agarwal, William Mieler

  • Challenging and educative cases from the experts are presented and discussed interactively among the panel
    Panellists: Mark Johnson, Jennifer Arnold

09:00 Coffee break

09:30 - 11:50
SESSION II: Artificial Intelligence in the management and understanding of retinal disease: Benefits and challenges

Moderators: Hrvoye Bogunovic, Ursula Schmidt-Erfurth

  • Hrvoje Bogunovicn: Introduction: Where is AI in retina in 2023?
  • Ramin Tadayoni: Fundus photography vs. OCT-A: The novel learnings
  • Tunde Peto: Shared care: Current achievements and perspectives
  • Gregor Reiter: AI-based fluid parameters in the management of neovascular AMD
  • Robert Avery: The role and promise of AI in the universe of the private practice

    10:10 Discussion
  • Daniela Ferrara: AI in Clinical Trails for Retinal Disease
  • Aaron Lee: The AI framework: Split or synchronized?
  • Joel S. Schuman: OCT and AI: How did and will the two connect?
  • Clarisa Sanchez: AI in retina: Which parameters and tools are fit for the clinic?
  • Aaron Lee: A foundation model for generalizable discuse detection frame

    11:20 Discussion
    11:50 Lunch Break

12:50 - 14:30
SESSION III: Unmet needs in the management of retinal disease

Moderators: Andreas Pollreisz, Paul Sternberg

  • Andreas Pollreisz: Introduction: The new diagnostic univers in diabetic retinopathy
  • Jennifer Arnold: Sub-threshold laser to early AMD: Rationale, benefit and risk
  • Catherine Cukras: Local and Global Associations of Reticular Pseudodrusen in AMD
  • Paul Sternberg: Addressing the challenges in managing the unmet needs of patients with atrophic AMD
  • Mark Johnson: Degenerative lamellar macular holes and other Muller gliopathies
  • Matus Rehak: A state-of-the art in DME management in the real world: What we are missing
  • Chang Ki Yoon: A comprehensive insight into Pseudodrusen and Function

    14:00 Discussion
    14:30 Break

15:00 -16:30
SESSION IV:  The future is here to stay: A close look on GA therapies
Moderators: Gregor Reiter, Sasha Fauser

  • Ursula Schmidt-Erfurth: Introduction
  • Roy Schwartz: Pioneering the field in GA therapy
  • Erin C. Henry: The Efficacy and Safety of Avacincaptad Pegol in Geographic Atrophy: 24-Month Results From GATHER2
  • Michael Tolentino: Heralding the Glycomic Revolution
  • Sascha Fauser: Treatment beyond intravitreal injection
  • Guillaume Normand: Beyond FAF: The role of AI in the profiling and management of GA
  • Jacob Pichelmann: Developing AI for clinical decision support systems (CDSS)

    16:00 Discussion
    16:30 End

Sponsored by

Gold Sponsoring

Bronze Sponsoring